pharmaphorum March 14, 2024
The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs from federal funding and contracts on national security grounds.
The bipartisan BIOSECURE Act was tabled earlier this year and, if enacted, would restrict US executive agencies from contracting with some overseas biotechnology providers on data security concerns. The bill mentioned contract development and manufacturing organisation WuXi AppTec and Chinese genomics specialist BGI Group by name.
Last week, a US Senate committee voted to approve the act, taking it one step closer to fruition and, while there is still a long way to go before it could become law, the BIO’s endorsement is a boost to...
Today's Sponsors
Today's Sponsor